Drug Trial Radar · NCT05038800
A Study to Evaluate MK-0482 for Relapsed/Refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML) (MK-0482-002)
Last checked: Nov 19, 2026Latest source record: May 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
13
Actual
Start
Sep 26, 2021
Primary completion
Dec 11, 2023
Study completion Dec 11, 2023
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Sep 9, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and recommended Phase 2 dose (RP2D) of MK-0482. There are 2 parts of this study. Part 1 is a dose escalation which will follow an accelerated titration design (ATD) for participants with relapsed/refractory (R/R) AML or CMML. Part 2 is a dose expansion for participants with R/R AML.
Conditions
- Relapsed or Refractory Acute Myeloid Leukemia
- Relapsed or Refractory Chronic Myelomonocytic Leukemia
Interventions
MK-0482Biological
IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Who Experienced a Dose-Limiting Toxicity (DLT)Time frame: Cycle 1 (up to 21 days)
- Number of Participants Who Experience at Least One Adverse Event (AE)Time frame: Up to approximately 10 months
- Number of Participants Who Discontinued Study Treatment Due to an AETime frame: Up to approximately 4 months
Locations
5 sites in 3 countries. Site status is shown where the registry gives one.
Roswell Park Cancer Institute ( Site 0006)
Buffalo, New York
University of Texas MD Anderson Cancer Center ( Site 0004)
Houston, Texas
Hadassah Medical Center ( Site 0100)
Jerusalem, Israel
Sheba Medical Center-Hemato Oncology ( Site 0101)
Ramat Gan, Israel
Hospital Universitario de Salamanca - Complejo Asistencial U-Servicio de Hematologia ( Site 0301)
Salamanca, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.